Report

Initiation: Promising anti-cancer drugs head to the clinic

Novogen is developing two groups of anti-cancer compounds that have
shown a great deal of promise in preclinical studies. Its super-benzopyran
drugs are highly potent against cancer stem cells that are resistant to
standard chemotherapy drugs, both in vitro and in animal models. Its lead
anti-tropomyosin dug, Anisina, shows strong synergy with standard-ofcare
anti-mitotic vinca alkaloid drugs. The company is well-funded, having
raised ~$26m in the past two months, and is on track to have its three lead
anti-cancer drugs in clinical trials by mid-2016. Its base case valuation is
$126m, or $7.45 per ADR (undiluted).
Underlying
Novogen Limited

Provider
Edison Investment Research
Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

.

Other Reports on these Companies
Other Reports from Edison Investment Research

ResearchPool Subscriptions

Get the most out of your insights

Get in touch